Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 2012

View Archived Issues

Leo Pharma prepares novel CaS receptor agonists

New lysophospholipid receptor modulators designed by Allergan

New safety data from SMART trials disclosed at ongoing conference

First clinical data reported on new whole-cell cancer vaccine

Significance of LMTK3 SNP explored in Japanese patients with gastric adenocarcinoma

Exelixis presents novel protein kinase inhibitors

Astex Pharmaceuticals patents new FGFR inhibitors

Novel FFA1 receptor agonists disclosed by Boehringer Ingelheim

Amgen divulges new agents for cognition disorders

Extended-release tablet has encouraging effects in patients with depression

Ablynx reports on phase II extension study of ozoralizumab

Lexicon discloses phase IIb data on LX-4211

MAP Pharmaceuticals updates on Levadex NDA

FDA issues complete response letter for Eliquis NDA

Peregrine completes recruitment in bavituximab trial

Milestone achieved in phase IIb tamibarotene study

New phase IIb study investigates RP-103 for NASH

CHMP recommends approval of Afinitor for new indication

Baxter immunoglobulin is the first to be approved in U.S. for MMN

Phase III iferanserin study does not meet endpoints

Neuralstem provides update on phase I trial in major depressive disorder

Novel candidate therapies for schizophrenia developed

European CHMP issues opinion on Humira for severe axial spondyloarthritis

Chugai files for Japanese approval of EGFR inhibitor as first-line therapy for NSCLC

Ongoing phase III rifampicin trial evaluates safety and efficacy in MSA

Rienso obtains E.U. approval

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...